Gout induced by L-dopa and decarboxylase inhibitors
- 1 April 1976
- journal article
- case report
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 52 (606) , 232-233
- https://doi.org/10.1136/pgmj.52.606.232
Abstract
Two cases of clinical gout are reported in parkinsonian patients receiving L-dopa in combination with a decarboxylase inhibitor. Blockade of decarboxylation leads to major changes in the pattern of L-dopa metabolites. It is suggested that hyperuricaemia may result from accumulation of L-dopa itself or a transaminated product.Keywords
This publication has 9 references indexed in Scilit:
- Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase InhibitionNature, 1974
- Parkinsonism treated with 3‐0‐methyldopaClinical Pharmacology & Therapeutics, 1973
- Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylaseJournal of the Neurological Sciences, 1972
- Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.1972
- Gout While Receiving Levodopa for ParkinsonismJAMA, 1972
- [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].1971
- False rise in serum uric acid after L-dopa.1969
- False Rise in Serum Uric Acid after L-DopaNew England Journal of Medicine, 1969